{"id":30379,"date":"2016-08-01T09:27:42","date_gmt":"2016-08-01T09:27:42","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=30379"},"modified":"2016-08-14T19:16:20","modified_gmt":"2016-08-14T19:16:20","slug":"dual-therapy-with-dolutegravir-3tc-keep-viral-load-undetectable-48-week-results-from-of-the-paddle-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/30379","title":{"rendered":"Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study"},"content":{"rendered":"

\"AIDSSimon Collins, HIV i-Base<\/strong><\/p>\n

Updated results from the PADDLE study were a highlight of AIDS 2016 and were presented as an oral late-breaker on the last day.<\/strong> [1]<\/p>\n

This was a small (n=20) single-arm open label study in treatment-naive participants that was notable for reporting at the EACS 2015 conference that rapid viral suppression to <50 copies by week 8 that was maintained to 24 weeks. Although median baseline viral load was low (24,000 copies\/mL [IQR: 12,000 to 37,000]), four people were >100,000 copies\/mL. [2]<\/p>\n

The results at week 48 were similar, with suppression maintained to <50 copies\/mL throughout in 18\/20 participants.<\/p>\n

Low level detectable viral load was reported at week 36 in one participant (at 246 copies\/mL) who resuppressed without a change in treatment (even though the study protocol recommended changing).<\/p>\n

One participant committed suicide linked to “severe stress and emotional trauma” that was not judged related to the study medications.<\/p>\n

Comment<\/h3>\n

These results are encouraging for the likelihood of this being a durable option, however small the dataset.<\/strong><\/p>\n

References:<\/p>\n

    \n
  1. Cahn P et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 48 week results of the PADDLE trial. AIDS 2016, 18-22 July 2016, Durban. Oral late breaker abstract FRAB0104LB.
    \nhttp:\/\/programme.aids2016.org\/Abstract\/Abstract\/10270<\/a>\u00a0(Abstract)
    \n    http:\/\/www.natap.org\/2016\/IAC\/IAC_92.htm<\/a>\u00a0(Slides thanks to natap.org)<\/li>\n
  2. Figueroa MI et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. 15th EACS, Barcelona 2015. Oral abstract LPBS 4\/1.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Updated results from the PADDLE study were a highlight of AIDS 2016 and were presented as an oral late-breaker on the last day. [1] This was a small (n=20) single-arm open label study in treatment-naive participants …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[224],"class_list":["post-30379","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-aids-21st-2016-durban"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=30379"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30379\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=30379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=30379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=30379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}